MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:31Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:5-alpha-reductase inhibitors]]
			[[Category:BPH treatments]]
			[[Category:Androgen modulators]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #91

2026-05-23T03:42:10Z

parser-claude batch MedTemplate pre-fill, Top 300 #91

New page

{{MedTemplate
| generic = Finasteride
| brand = Proscar (5 mg, BPH), Propecia (1 mg, alopecia)
| structure =
| classes = [[:Category:5-alpha-reductase_inhibitors|5α-reductase inhibitor]], [[:Category:BPH_treatments|Benign prostatic hyperplasia treatment]], [[:Category:Androgen_modulators|Androgen modulator]]
| uses = <vote slug="bph-use">Benign prostatic hyperplasia</vote>, <vote slug="androgenetic-alopecia-use">Androgenetic alopecia (male pattern hair loss)</vote>, <vote slug="hirsutism-trans-use">Off-label: hirsutism, feminizing GAHT adjunct</vote>
| starting_dose = 5 mg PO daily for BPH; 1 mg PO daily for androgenetic alopecia
| preparations = 1 mg, 5 mg tablets
| fda_max = 5 mg/d
| pill_id =
| routes = Oral
| onset = BPH symptom improvement at 3-6 months; prostate volume reduction over 6-12 months; hair regrowth at 6-12 months
| duration = 24 hours
| halflife = ~5-6 hours in young men, ~8 hours in elderly<ref name="proscar-label">FDA Prescribing Information, Proscar (finasteride), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020180s044lbl.pdf</ref>
| bioavailability = ~63% (oral)<ref name="proscar-label" />
| pregnancy = '''Pregnant individuals should not handle crushed/broken tablets''' (skin absorption risk); can cause hypospadias in male fetus. Not used in pregnancy.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="finasteride-mech-claim">Finasteride is a selective inhibitor of type II 5α-reductase, the dominant prostatic isoform converting testosterone to dihydrotestosterone (DHT); DHT lowering ~70% shrinks androgen-dependent prostatic tissue and the dermal papilla of androgen-sensitive hair follicles.</vote> Dutasteride inhibits both type I and II isoforms with deeper DHT suppression but a similar clinical effect. Post-finasteride syndrome (persistent sexual and mood effects after discontinuation) is a controversial but recognized clinical concern that the FDA acknowledged in 2012 labeling<ref name="proscar-label" />.
}}

== References ==
<references />

Finasteride - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #91